US20210260006A1 - Extended release dosage forms of pregabalin - Google Patents
Extended release dosage forms of pregabalin Download PDFInfo
- Publication number
- US20210260006A1 US20210260006A1 US17/313,274 US202117313274A US2021260006A1 US 20210260006 A1 US20210260006 A1 US 20210260006A1 US 202117313274 A US202117313274 A US 202117313274A US 2021260006 A1 US2021260006 A1 US 2021260006A1
- Authority
- US
- United States
- Prior art keywords
- pregabalin
- component
- release
- composition
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 169
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 161
- 238000013265 extended release Methods 0.000 title claims abstract description 106
- 239000002552 dosage form Substances 0.000 title description 19
- 239000000203 mixture Substances 0.000 claims abstract description 141
- 239000004480 active ingredient Substances 0.000 claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 208000035475 disorder Diseases 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims abstract description 14
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims abstract description 14
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 12
- 206010015037 epilepsy Diseases 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 229920000642 polymer Polymers 0.000 claims description 76
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 48
- 239000011324 bead Substances 0.000 claims description 41
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 40
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 40
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 40
- 239000001856 Ethyl cellulose Substances 0.000 claims description 35
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 35
- 229920001249 ethyl cellulose Polymers 0.000 claims description 35
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 29
- 239000008185 minitablet Substances 0.000 claims description 28
- 239000011248 coating agent Substances 0.000 claims description 27
- 238000000576 coating method Methods 0.000 claims description 27
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 26
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 26
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 26
- 239000000314 lubricant Substances 0.000 claims description 23
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- 239000011159 matrix material Substances 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 238000013270 controlled release Methods 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940049654 glyceryl behenate Drugs 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010026749 Mania Diseases 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940057948 magnesium stearate Drugs 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 239000000021 stimulant Substances 0.000 claims description 3
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 abstract description 45
- 206010010904 Convulsion Diseases 0.000 abstract description 8
- 208000004296 neuralgia Diseases 0.000 abstract description 7
- 208000021722 neuropathic pain Diseases 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000012423 maintenance Methods 0.000 abstract description 4
- 230000009977 dual effect Effects 0.000 abstract description 3
- 230000002045 lasting effect Effects 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 35
- 239000003826 tablet Substances 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 14
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- -1 but not limited to Chemical compound 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 229960003943 hypromellose Drugs 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000007903 gelatin capsule Substances 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 229920003091 Methocel™ Polymers 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229940009697 lyrica Drugs 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229940081735 acetylcellulose Drugs 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- 229940031954 dibutyl sebacate Drugs 0.000 description 5
- 239000007919 dispersible tablet Substances 0.000 description 5
- 239000012734 extended-release (ER) formulation Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000005563 spheronization Methods 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 229960002870 gabapentin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229940039028 pregabalin 300 mg Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000012443 tonicity enhancing agent Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010061334 Partial seizures Diseases 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000001815 ascending colon Anatomy 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000011363 dried mixture Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000009478 high shear granulation Methods 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229940039040 pregabalin 100 mg Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229920003176 water-insoluble polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical class Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001615 alkaline earth metal halide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001574 benzoxonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical class OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical class [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000005498 phthalate group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical class [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical class OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Abstract
The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.
Description
- This application is a continuation application of U.S. application Ser. No. 16/318,308, filed Jan. 16, 2019, which is a 35 U.S.C. 371 National Phase Entry Application from PCT/IL2017/050802, filed Jul. 16, 2017, which claims the benefit of U.S. Provisional Patent Application No. 62/363,267 filed on Jul. 17, 2016, the disclosures of which are incorporated herein in their entirety by reference.
- The present invention relates to once-daily, extended-release dosage forms of pregabalin having a dual extended-release profile, and use thereof in treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.
- Pregabalin is an anticonvulsant drug used to treat neuropathic pain and as adjunct therapy for partial seizures with or without secondary generalization in adults. It has also been found effective for generalized anxiety disorder and is approved for this use in the European Union. It is typically considered as a successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica® as immediate release hard shell capsules containing lactose and starch as inactive ingredients. Pregabalin is also used to treat epilepsy, post-herpetic neuralgia, and diabetic peripheral neuropathy. Recent studies have shown that pregabalin is effective at treating chronic pain in disorders such as fibromyalgia and spinal cord injury. Pregabalin is the first medication approved by the U.S. Food and Drug Administration specifically for the treatment of fibromyalgia. Pregabalin is available in 25, 50, 75, 100, 150, 200, 225, and 300 mg capsules, as well as in an oral solution containing 20 mg/mL pregabalin with a sweetening agent to mask the chemical's bitter taste. The maximum daily recommended dose for pregabalin in some indications is 600 mg.
- Currently, the main indications and doses approved for Pregabalin are: 1) management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), 100 mg 3× daily (300 mg); 2) post herpetic neuralgia (PHN), 75-150 mg 2× daily or 50-100 mg 3× daily (max 300 mg which can be increased to 600 mg in particular cases); 3) as adjunctive therapy for adults with partial onset seizures (150-600 mg/day given in 2-3 doses); and 4) management of fibromyalgia (300-450 mg/day−given in 2-3 doses).
- The current dosing regimen of 2-3 daily doses is problematic due to significant compliance issues, and due to clinical side effects which result from the sharp increase in blood plasma levels of the drug following immediate release doses. Moreover, widely fluctuating plasma concentrations of the drug may result in administration of less than therapeutic amounts of the drug in a conservative dosing regimen, or amounts too large for the particular patient in an aggressive dosing regimen.
- It is therefore desired to develop a once daily dosage form which will replace the currently marketed immediate release formulations. However, development of a once daily dosage form of pregabalin is challenging due to its unique absorption characteristics: pregabalin is well absorbed in the small intestine, and in the proximal regions of the colon (caecum, ascending colon). However, its absorption in the distal colon (hepatic flexure to rectum) is poor. This basic characteristic is considered to be the main obstacle in developing a once-daily regimen of this drug.
- A few attempts to develop a once daily formulation of pregabalin are mentioned in the literature, most based on the development of Gastro-Retentive dosage forms which attempt to prolong the retention time of the drug in the upper parts of the GI where it is preferably absorbed.
- PCT International Patent Application WO 2005/041924 (corresponding to US 2005/0163848) relates to a complex comprised of pregabalin and a transport moiety, such as an alkyl sulfate. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositions and dosage forms prepared using the complex, provide for absorption by the body of the drug through a period often to twenty-four hours, thus allegedly enabling a once-daily dosage form for pregabalin.
- PCT International Patent Application WO 2006/078811 relates to pregabalin formulations which comprise up to three components including an immediate release component, a sustained release component and a delayed release component. The formulations comprise (a) an active ingredient such as pregabalin coated by a pH independent soluble polymer excipient; (b) an active ingredient such as pregabalin coated by a pH independent insoluble polymer excipient; and (c) an active ingredient such as pregabalin coated by a pH dependent soluble polymer excipient. The formulation is adapted to release the active ingredient in three phases. In the first phase, the active ingredient is released rapidly in the stomach; in the second phase, the active ingredient is released over a sustained release period mainly in the lower stomach, duodenum and jejunum sections of the small intestine; and in the third phase, the release of the active ingredient is delayed until the jejunum and ileum sections of the small intestine, wherein pregabalin is released rapidly.
- PCT International Patent Application WO 2007/052125 relates to a pharmaceutical composition comprising pregabalin, a matrix forming agent and a swelling agent, the matrix-forming agent comprising polyvinyl acetate and polyvinylpyrrolidone, and the swelling agent comprising cross-linked polyvinylpyrrolidone, wherein the pharmaceutical composition is adapted for once-daily oral dosing.
- PCT International Patent Application WO 2009/066325 relates to controlled release pharmaceutical compositions comprising pregabalin or salts thereof, a hydrophobic release controlling agent(s) and optionally other pharmaceutically acceptable excipients.
- PCT International Patent Application WO 2011/049309 (corresponding to US 2011/217374) discloses a pharmaceutical composition comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier.
- PCT International Patent Application WO 2011/053003 teaches gastric-retentive sustained release formulations containing pregabalin or a pharmaceutically acceptable salts thereof, polyethyleneoxide, and polyvinylalcohol-polyethyleneglycol graft copolymer, in which a swelling property and floatability of matrix is improved by using a polyethyleneoxide and polyvinylalcohol-polyethyleneglycol graft copolymer, thereby controlling the release of the drug.
- U.S. Pat. No. 7,731,989 relates to a dosage form comprising between about 100 mg to about 4800 mg of gabapentin dispersed in a polymer matrix comprising at least one swellable hydrophilic polymer that swells unrestrained dimensionally in water to a size to promote gastric retention of the dosage form in a stomach in a fed mode, wherein upon contact with water, gabapentin is released by diffusion from the dosage form over a period of at least five hours and at least 40 wt % of the gabapentin is retained in the dosage form 1 hour after administration.
- United States Patent Application US 2002/0119197 relates to a pharmaceutical dosage form comprising a central core including a pharmaceutical agent in a controlled-release composition, said core having two exposed opposite end surfaces and a peripheral surface at an outer edge of said core extending between said two opposed end surfaces, said peripheral edge surrounded by a diffusion-limiting sleeve, wherein said sleeve limits the diffusion of fluids into said core.
- Chinese Patent Application CN 1857244 relates to a slow release pregabalin composition, which includes pregabalin or its medicinal salt in the effective treating dosage of 50-1000 mg and at least one release speed controlling material. The composition releases pregabalin in at least 10 to 24 hours.
- Indian Patent Application IN 2009DE01649 discloses an extended-release floating tablet comprising pregabalin, a gas generating component, at least one rate-controlling polymer and other pharmaceutical excipients, wherein the tablet provides therapeutically effective plasma levels of pregabalin for a period of up to about 24 h.
- Several clinical trials are currently being conducted to test extended release formulations of pregabalin: 1) Phase I and PK comparing a pregabalin ER once daily formulation (doses 82.5, 165, 330 mg) to an immediate-release formulation given b.i.d. or t.i.d.; 2) a Phase II study evaluating a once daily formulation comprising 165-498 mg pregabalin for the treatment of fibromyalgia; and 3) a Phase III study evaluating a once daily formulation comprising 82, 165 and 330 mg pregabalin for the treatment of partial seizures and epilepsies.
- At present, no controlled-release formulations of pregabalin are approved. This is an unmet medical need due to the unique absorption characteristics of pregabalin.
- The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which release the pregabalin active ingredient according to a dual extended release profile. The compositions of the invention are adapted to the unique release characteristics of pregabalin and comprise two components, the first providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. In some embodiments, the first component (designated herein “fast ER”) is the minor portion (i.e., it makes up less than 50% of the composition) while the second component (designated “slow ER” or “maintenance”) is the major portion (i.e., it makes up more than 50% of the formulation). In other embodiments, the first component is the major portion (i.e., it makes up more than 50% of the composition) while the second component is the minor portion (i.e., it makes up less than 50% of the formulation). The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.
- Due to the absorption characteristics of pregabalin following oral administration, it is desired to formulate this compound in a composition which enables its controlled release. The formulations of the present invention provide improved pharmacokinetics of the active ingredient while minimizing side effects due to lower index of fluctuations. The present invention is based on the improved absorption of pregabalin in the upper parts of the GI, and its limited absorption at the lower parts of the colon. The release pattern of the formulations of the invention is biphasic, and is adapted to the unique release characteristics of pregabalin, whereby, in some embodiments, a portion of the dose is released on a “fast ER” manner and the rest of the dose is released in the “slow ER” manner According to the principles of the present invention, the formulations release the pregabalin active ingredient in two separate but parallel release profiles: a portion of the daily dose is released in a short controlled manner lasting about 4-6 hrs (fast ER), while the rest of the daily dose is provided in a controlled 24 hrs release pattern (slow ER or maintenance component). The dosage forms are controlled or extended release formulations given preferably once daily (preferably given after meals and at bedtime).
- According to one aspect, the present invention provides an oral, extended-release (ER) pharmaceutical composition comprising as an active ingredient pregabalin or a salt thereof and a pharmaceutically acceptable carrier or excipient, wherein the composition comprises a first component that provides release of the pregabalin active ingredient over a time period of about 4 to about 6 hours, and a second component that provides release of the pregabalin active ingredient over a time period of about 24 hours. Preferably, the composition is adapted for once-daily administration.
- In some embodiments, the proportions in each dose between the first component (fast or short extended release over 4-6 hrs) and the second component (slow or longer extended release over 24 hrs) is between about 50%:50% (wt/wt) to about 10%:90% (wt/wt), preferably from about 25%:75% (wt/wt) to about 10%:90% (wt/wt), for example about 15%:85% (wt/wt), about 30%:70% (wt/wt), or about 40%:60% (wt/wt). Each possibility represents a separate embodiment of the present invention.
- In other embodiments, the proportions in each dose between the first component (short extended release over 4-6 hrs) and the second component (longer extended release over 24 hrs) is between about 50%:50% (wt/wt) to about 90%:10% (wt/wt), preferably from about 75%:25% (wt/wt) to about 90%:10% (wt/wt), for example about 85%:15% (wt/wt), about 70%:30% (wt/wt), or about 60%:40% (wt/wt). Each possibility represents a separate embodiment of the present invention. The compositions of the invention generally contain a total amount of from about 50 mg to about 600 mg of pregabalin or a salt thereof, wherein the total dose is divided between the first and the second components.
- In some embodiments, each of the first component and the second component each independently comprises at least one pharmaceutically acceptable excipient selected from the group consisting of a release controlling polymer, a binder, a glidant, a plasticizer, a matrix former, a disintegrant, a lubricant, and any combination thereof.
- In some embodiments, the first component and/or the second component of the formulation each independently comprises at least one release controlling polymer selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose (EC), cellulose acetate, acrylic polymers, polyvinylpyrrolidone (PVP), or combinations thereof. Currently preferred release controlling polymers are hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose (EC), and combinations thereof. Each possibility represents a separate embodiment of the present invention.
- In other embodiments, the binder is selected from the group consisting of hydroxypropyl cellulose (HPC) and polyvinylpyrrolidone (PVP). In other embodiments, the lubricant is selected from the group consisting of magnesium stearate, glyceryl behenate and sodium stearyl fumarate. In other embodiments, the glidant is silicon dioxide.
- The first component may be the same or different from the second component in composition. For example, each component may comprise the same or different polymers in any proportion. In some embodiments, the composition of the two components is the same, but different amounts thereof are used in order to achieve the desired release profiles. For the purpose of illustration, when coated extended release beads or mini-tablets are used, the same coating can be used for both the fast ER and slow ER populations, with different amounts of each coating in each portion. Alternatively, the fast ER component may be in the form of uncoated beads or mini-tablets, and the slow ER component may be in the form of coated beads or mini-tablets. Each possibility represents a separate embodiment of the present invention. In various embodiments, the active ingredient in each of the components of the formulation is released in a controlled release order selected from zero, first, second and third release order, and any pseudo orders thereof. The release order of each component can be the same or different from the other component. Each possibility represents a separate embodiment of the present invention.
- In some embodiments, the pregabalin active ingredient is released from the pharmaceutical composition to provide a lower Cmax, a smaller index of fluctuation, and/or a reduced side effects profile as compared to a substantially similar dose of an immediate release formulation of pregabalin (e.g., Lyrica®).
- In some embodiments, the composition of the present invention is in a form selected from ER beads, mini-tablets, double-layer tablets, hard or soft gelatin capsule, a pellet, or combinations thereof. In some embodiments, the composition of the invention is in the form of ER beads or mini tablets filled into hard or soft gelatin capsules or compressed into dispersible tablets. Mixtures of any of the above are also contemplated. Each possibility represents a separate embodiment of the invention.
- In one particular embodiment of the compositions of the invention, the first component and the second component are each in the form of ER beads or mini-tablets that are filled into hard or soft gelatin capsules or compressed into dispersible tablets. Each component may comprise the same or different polymers in any proportion. In some embodiments, the composition of the two components is the same, but different amounts thereof are used in order to achieve the desired release profiles. For the purpose of illustration, when coated mini-tablets are used, the same coating can be used for both the fast ER and slow ER populations, with different amounts of each coating in each portion. Alternatively, the fast ER component may be in the form of uncoated mini-tablets or ER beads, and the slow ER component may be in the form of coated mini-tablets or ER beads. Each possibility represents a separate embodiment of the present invention.
- In some embodiments, the first component and the second component are each in the form of ER beads or mini-tablets comprising pregabalin, a first release controlling polymer and at least one lubricant and/or matrix former, wherein the first component is uncoated and wherein the second component further comprises a coating comprising second release controlling polymer which may be the same or different from the first release controlling polymer. In specific embodiments, the first component and the second component are each in the form of ER beads or mini-tablets comprising pregabalin, ethyl cellulose, glyceryl behenate and magnesium stearate, wherein the first component is uncoated and wherein the second component further comprises a coating comprising ethyl cellulose.
- In other embodiments, the first component and the second component are each in the form of ER beads or mini-tablets comprising pregabalin, a first release controlling polymer, at least one lubricant and/or matrix former, and a coating comprising a second release controlling polymer which may be the same or different from the first release controlling polymer, wherein the same coating in different amounts, is used for the first and second components. In some embodiments, the extended release dosage forms of the invention are prepared by two optional technologies: extruder and spheronization followed by coating, e.g., in a Wurster column; or multilayer coating over inert sugar spheres (NPs), for example in a fluid bed equipped with Wurster. In some embodiments, ER beads of the invention are prepared by layering over sugar spheres, or by extrusion and spheronization. In other embodiments, mini-tablets or double-layer tablets of the invention are prepared by granulation or direct compression. Each possibility represents a separate embodiment of the invention.
- The pharmaceutical compositions of the present invention are useful in treating a condition or disorder which is responsive to pregabalin treatment. Thus, in additional embodiments, the present invention relates to a method of treating a condition or disorder which is responsive to pregabalin treatment, by administering an effective amount of the extended-release formulations of the present invention as described herein. In other embodiments, the present invention relates to the use of the extended-release formulations of the invention as described herein, for treating a condition or disorder which is responsive to pregabalin treatment. In other embodiments, the present invention relates to the use of the extended-release formulations of the invention as described herein, for treating a condition or disorder which is responsive to pregabalin treatment.
- In some embodiments, the condition or disorder which is responsive to pregabalin treatment is selected from epilepsy, pain, diabetic peripheral neuropathy, postherpetic neuralgia, physiological condition associated with psychomotor stimulants, inflammation, gastrointestinal damage, alcoholism, insomnia, fibromyalgia, anxiety, depression, mania and bipolar disorder, and any combinations thereof. Each possibility represents a separate embodiment of the invention.
- Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
-
FIG. 1 depicts the plasma concentration vs. time profile of a pregabalin extended release (ER) formulation according to the present invention (∘) and pregabalin immediate release (IR) (▪) formulation (Lyrica®). -
FIG. 2 depicts the in vitro (♦) and in vivo (▴) release profile of a pregabalin extended release (ER) formulation according to the present invention. - The present invention relates to novel once-daily, extended-release dosage forms of pregabalin, and use thereof in treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.
- Pregabalin as used herein is the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, which is a derivative of gamma-amino butyric acid (GABA). The structure of pregabalin is represented below.
- It is contemplated that any pharmaceutically acceptable form of pregabalin including, but not limited to, salts (e.g. the HCl or alkaline metal salts), solvates (e.g., hydrates), isomorphs, polymorphs, pseudopolymorphs, and pro-drugs are within the scope of the present invention.
- The present invention provides an extended release formulation which enables the controlled release of the active ingredient, pregabalin, according to two separate release profiles: a first component of the composition is released over a time period of 4-6 hours, while a second component of the formulation, provides a “maintenance dose” of the pregabalin active ingredient released over a time period of up to 24 hours. Together, the two components provide long-lasting, continuous therapeutic exposure to the drug. The proportion of the first component and the second component in the composition may vary according to the intended use and desired release profile of the composition. In some embodiments, the first (fast ER) component is released in the stomach up to the ascending colon, while the second (slow ER) component is released throughout the entire GI tract.
- Formulations
- Provided herein are oral pharmaceutical compositions which provide controlled release of the active ingredient, pregabalin, or a salt thereof according to a biphasic profile, which each component releasing the pregabalin active ingredient according to a particular release profile. The oral, extended-release (ER) pharmaceutical compositions comprise pregabalin or a salt thereof as an active ingredient, wherein the composition comprises a first component that provides release of the pregabalin active ingredient over a time period of about 4 to about 6 hours, and a second component that provides release of the pregabalin active ingredient over a time period of about 24 hours. Preferably, the composition is adapted for once-daily administration.
- In various embodiments, the active ingredient in each of the components of the formulation is released in a controlled release order selected from zero, first, second and third release order, and any pseudo orders thereof. The release order of each component can be the same or different from the other component. Each possibility represents a separate embodiment of the present invention. It is contemplated that upon administration, the pharmaceutical compositions of the present invention provide lower Cmax values and/or smaller index of fluctuation of the active ingredient in the circulation of a subject, thus leading to reduced side-effects as compared to the conventional immediate release dosage forms comprising substantially the same dose.
- In some embodiments, the composition of the present invention is in a form selected from ER beads, mini-tablets, double-layer tablets, hard or soft gelatin capsule, a pellet, or combinations thereof. ER beads and mini-tablets are currently preferred embodiments. In some embodiments, the composition of the invention is in the form of ER beads or mini tablets filled into hard or soft gelatin capsules or compressed into dispersible tablets. Mixtures of any of the above are also contemplated. Each possibility represents a separate embodiment of the invention.
- As used herein, the term “controlled release” (CR) refers to the type of oral dosage form compositions and release patterns, wherein the active ingredient, pregabalin or salt thereof, is released gradually over a period of time or at predetermined intervals. According to the principles of the present invention, the term CR further encompasses sustained release (SR) or extended-release (ER) formulations of pregabalin or salt thereof.
- According to one embodiment, the ER pharmaceutical compositions of the present invention comprise a first component (fast ER component) comprising at least one polymer which allows for release of the active ingredient over a short, controlled release period of about 4-6 hours. Preferably, such polymer is selected from the group consisting hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose (EC), Cellulose acetate, acrylic polymers (including acrylic acid polymers, acrylate ester polymers etc.), polyvinylpyrrolidone (PVP), or combinations thereof. In one currently preferred embodiment, the polymer in the first (fast ER) component is hydroxypropyl cellulose (HPC). In another currently preferred embodiment, the polymer in the first (fast ER) component is hydroxypropylmethyl cellulose (HPMC), such as Hypromellose. In another currently preferred embodiment, the polymer in the first (fast ER) component is ethyl cellulose (EC), such as Surelease® EC dispersion, or Ethocel™.
- Other examples of suitable polymers include, but are not limited to hydrolyzed polyvinylalcohol, polyethylene oxide, a vinyl polymer, dextran, guar gum, pectin, starch, a cellulosic polymer, and any combination thereof. Each possibility represents a separate embodiment of the present invention. Acrylic polymers include, but are not limited to, polymers known as “carbomers”, (e.g., Carbopol®, from B.F. Goodrich) and Carbopol® 934. Polyethylene oxides include, but are not limited to, Sentry Polyox® water soluble resins DOW. Polyacrylates include Eudragit® (available from Rohm). Cellulosic polymers include, but are not limited to, hydroxypropyl methylcellulose (e.g., Methocel® from the Dow Chemical Company); hydroxypropyl cellulose (e.g., Klucel® from Hercules); hydroxypropyl cellulose ethers; ethyl cellulose; methyl cellulose, Na carboxymethylcellulose and the like. Each possibility represents a separate embodiment of the present invention.
- The pharmaceutical compositions of the invention also comprise a second component (slow ER component) comprising at least one polymer which allows for release of the active ingredient over a longer, controlled release period of about 24 hours. The polymer of the slow ER component is selected from among the list provided above for the polymer of the fast ER component. The polymer(s) in the second component may be the same or different from the polymer(s) in the first component, with each possibility representing a separate embodiment of the present invention. In one currently preferred embodiment, the polymer in the second (fast ER) component is hydroxypropyl cellulose (HPC). In another currently preferred embodiment, the polymer in the second (fast ER) component is hydroxypropylmethyl cellulose (HPMC). In another currently preferred embodiment, the polymer in the second (fast ER) component is ethyl cellulose (EC). To achieve a longer release period, the release controlling polymer of the second component may be used in different amounts than in the first component, or the polymer may be incorporated into a slow release coating layer which is applied onto the fast ER component. Alternatively, both the slow ER release and fast ER release components may contain a coating comprising a release controlling polymer, wherein the coating is applied in different ratios to achieve the desired release profile.
- The first component may be the same or different from the second component in the composition. For example, each component may comprise the same or different polymers in any proportion. In some embodiments, the two components comprise the same polymers/other excipients, but different amounts thereof are used in order to achieve the desired release profiles. For the purpose of illustration, when coated extended release beads or mini-tablets are used, the same polymeric coating can be used for both the fast ER and slow ER populations, with different amounts of each coating being used for each component. In another illustrative example, when extended release beads or mini-tablets are used, the first component may be an uncoated composition, and the second component may be the same composition as the first component, further including a coating comprising a release controlling polymer, the amount of which may be varied according to the desired release profile.
- The present invention is also directed to a once-daily composition wherein the AUC drug plasma level of the pregabalin is substantially the same or equivalent to that obtainable for an equivalent cumulative daily dose of conventional immediate release pregabalin e.g., that sold under the trademark Lyrica®. The present invention may determine AUC as either by the integration of the data points from time zero to time infinity, when those data points are concentrations (levels) of pregabalin in plasma following single doses of pregabalin as Lyrica® in healthy volunteers, and/or in the target patient population.
- The pharmaceutical compositions of the present invention may further include additives known to the person with skill in the art. For example, the composition may further comprise stabilizers, tonicity enhancing agents, buffering substances, preservatives, thickeners (viscosity enhancing), matrix formers (also designated herein as matrix forming agents), fillers, glidants, disintegrants, plasticizers, diluents, binders, emulsifying agents, lubricants, wetting agents, flavoring agents, colorants, complexing agents, and other excipients such as maize starch, wheat starch, rice starch, potato starch and the like, gelatin, gum tragacanth, caranauba wax, glyceryl tristearate, cellulose based excipients as microcrystalline cellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose, hydroxypropylcellulose and the like. Each possibility represents a separate embodiment of the present invention.
- Other excipients include enteric polymers and surface active agents. A variety of materials can be used as enteric polymers, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. A suitable surface active agent is e.g. sodium lauryl sulfate.
- Suitable fillers include, but are not limited to, sugars such as lactose, sucrose, mannitol or sorbitol, ethylcellulose, microcrystalline cellulose, silicified microcrystalline cellulose and the like. Each possibility represents a separate embodiment of the present invention. A suitable glidant is e.g., colloidal silicon dioxide or talc.
- Suitable tonicity enhancing agents are selected from ionic and non-ionic agents. For example, ionic compounds include, but are not limited to, alkali metal or alkaline earth metal halides, such as, for example, CaCl2 KBr, KCl, LiCl, Nal, NaBr or NaCl, or boric acid. Non-ionic tonicity enhancing agents are, for example, urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose. Each possibility represents a separate embodiment of the present invention.
- Examples of preservatives are quaternary ammonium salts such as benzalkonium chloride, benzoxonium chloride or polymeric quaternary ammonium salts, alkyl-mercury salts of thiosalicylic acid, such as, for example, thiomersal, phenylmercuric nitrate, phenylmercuric acetate or phenylmercuric borate, parabens, such as, for example, methylparaben or propylparaben, alcohols, such as, for example, chlorobutanol, benzyl alcohol or phenyl ethanol, guanidine derivatives, such as, for example, chlorohexidine or polyhexamethylene biguanide, or sorbic acid. Each possibility represents a separate embodiment of the present invention.
- Disintegrants include, but are not limited to, cross-linked polyvinylpyrrolidones, cross-linked carboxylic methylcelluloses, calcium silicate, sodium carboxymethyl starches, methylcellulose; agar bentonite; calcium carbonate; polyoxyethylene sorbitan fatty acid esters, stearic monoglyceride, cornstarch, potato starch, silicon dioxide, croscarmelose sodium, crospovidone, guar gum, sodium starch glycolate and lactose. Each possibility represents a separate embodiment of the present invention.
- Plasticizers include dibutylsebacate, polyethylene glycol, e.g. Macrogol 400, 6000 or 8000, polypropylene glycol, glycerin, sorbitol, maltitol, glucose, sucrose, lanolin, palmitic acid, oleic acid, stearic acid, metallic salts of fatty acids, glyceryl lecithin, glyceryl monostearate, propylene glycol monostearate, acetylated glycerides, alkyl esters of citric acid such as triethyl citrate, tributyl citrate, acetyl tributyl citrate or acetyl triethyl citrate, phtalates such as diethyl phthalate, waxes, hydrogenated vegetable oils, and mixtures thereof.
- Suitable diluents include, but are not limited to, dicalcium phosphate dehydrate, sugars, lactose, calcium phosphate, cellulose, kaolin, mannitol, sodium chloride, and dry starch. Each possibility represents a separate embodiment of the present invention.
- Suitable binders include, but are not limited to, water, ethanol, polyvinylpyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC such as Hypromellose), starch, gelatin, or sugars. Sugars include sucrose, dextrose, molasses, and lactose. Each possibility represents a separate embodiment of the present invention. Thickeners (viscosity enhancing agents) such as polyvinyl alcohol (PVA) may also be used part of the slow release system.
- Suitable lubricants include, but are not limited to, stearic acid, polyethylene glycol, glycerol derivatives such as Glyceryl Behenate (which can also can function as a binder, or matrix former) or stearates, such as magnesium stearate or sodium stearyl fumarate. Each possibility represents a separate embodiment of the present invention. Suitable wetting agents include, but are not limited to, glycerin, starches, and the like.
- Suitable buffering agents or buffering substances include, but are not limited to, acidic buffering agents such as short chain fatty acids, citric acid, acetic acid, hydrochloric acid, sulfuric acid and fumaric acid; and basic buffering agents such as tris, sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide and magnesium hydroxide. Each possibility represents a separate embodiment of the present invention.
- The compositions of the present invention may further comprise a taste-masking layer. Suitable taste-masking layer includes, but is not limited to, a layer comprising ethylcellulose, polyvinyl acetate (PVA), cellulose acetate (CA), cellulose acetate butyrate (CAB), methacrylate copolymers, such as those available under the tradename “EUDRAGIT” (e.g., type L, S, RL, RS, and NE30D), and combinations thereof. Each possibility represents a separate embodiment of the present invention.
- The amount and type of excipient added is in accordance with the particular requirements and is generally in the range of from approximately 0.0001 to approximately 90% of the composition by weight.
- In some embodiments, the formulations further comprise a subcoating layer which separates the active drug phase from the functional external coating(s). An example of an excipient for the subcoat is polyvinyl alcohol (PVA).
- Within the scope of the present invention is a pharmaceutical composition in the form of ER beads, mini-tablets, double-layer tablets, hard or soft gelatin capsule, a pellet, or combinations thereof. In some embodiments, the composition of the invention is in the form of ER beads or mini tablets filled into hard or soft gelatin capsules or compressed into dispersible tablets. Mixtures of any of the above are also contemplated. Each possibility represents a separate embodiment of the invention. According to the principles of the present invention tablet forms include, but are not limited to, bilayer tablets which comprise two or more distinct layers of granulation compressed together with the individual layers lying one on top of another, with each separate layer containing the active ingredient formulated to be released in a separate manner. In one embodiment, the invention is directed to a tablet in which the active agent is present in two separate layers, i.e. a bi-layer tablet, in which the layers comprising the agent may be separated by an intermediate, inactive layer.
- In some embodiments, the extended release dosage forms of the invention are prepared by two optional technologies: extruder and spheronization followed by coating, e.g., in a Wurster column, or multilayer coating over inert sugar spheres (NP's), for example in fluid bed equipped with Wurster. Thus, in some embodiments, the ER beads of the invention are prepared by layering over sugar spheres, or by extrusion and spheronization. In other embodiments, the mini-tablets or double-layer tablets of the invention are prepared by granulation or direct compression. Each possibility represents a separate embodiment of the invention.
- The pharmaceutical composition of the present invention may also comprise the microencapsulation of the active ingredient. In accordance with these embodiments, small particles of the active ingredient, pregabalin, are surrounded by a coating or a membrane to form particles in the range of a few micrometers to a few millimeters.
- The composition of the present invention may further be mixed and filled into a capsule or sachet or is compressed to a dispersible tablet by conventional methods.
- The pharmaceutical compositions of the present invention can also be manufactured using conventional processes as is known in the art. For example, solid compositions such as tablets can be prepared by wet granulation, dry granulation, direct compression and the like. Suitable preparations comprise mixing the principal active ingredient with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- Administration and Therapeutic Use
- The present invention further provides a method of administering a composition of the present invention to a mammal, preferably a human. It is contemplated that the compositions described herein are administered by an oral route to afford transmucosal or gastrointestinal absorption of pregabalin. The desired dose may conveniently be presented in a single dose or as a divided dose administered at appropriate intervals, but preferably the compositions of the present invention are formulated for once-daily dosing.
- The amount of a composition to be administered depends on various factors including the subject being treated (age and gender), the severity of the disease, and can be determined by the judgment of the prescribing physician. In certain embodiments, the compositions are in unit dosage forms. The pharmaceutical compositions of the present invention may contain any dosage of pregabalin, preferably a total of from about 50 mg to about 600 mg pregabalin or a salt thereof wherein the total amount is divided between the first and second components of the composition as desired. As yet another aspect of this invention is directed to the composition wherein pregabalin is in a dose of a formulation totaling about 600 mg, 550 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 200 mg, 150 mg, 100 mg, or 50 mg of the pregabalin active ingredient.
- The pregabalin dose is divided among the first and second component of the formulation according to any proportion. In some embodiments, the first component comprises the majority of the pregabalin active ingredient, i.e., more than 50% of the pregabalin in the composition.
- In some embodiments, the proportions in each dose between the first component (fast extended release over 4-6 hrs) and the second component (slow extended release over 24 hrs) is between about 50%:50% (wt/wt) to about 90%:10% (wt/wt), preferably from about 75%:25% (wt/wt) to about 90%:10% (wt/wt), for example about 85%:15% (wt/wt), about 70%:30% (wt/wt) or about 60%:40% (wt/wt). Each possibility represents a separate embodiment of the present invention. Preferably, the first component comprises 50% or more of the pregabalin active ingredient, for example 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the total pregabalin dose. Preferably, the second component comprises 50% or less of the pregabalin active ingredient, for example 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the total pregabalin dose. Any combination of such proportion is encompassed by the scope of the present invention. Each possibility represents a separate embodiment of the present invention.
- In other embodiments, the proportions in each dose between the first component (fast extended release over 4-6 hrs) and the second component (slow extended release over 24 hrs) is between about 50%:50% (wt/wt) to about 10%:90% (wt/wt), preferably from about 25%:75% (wt/wt) to about 10%:90% (wt/wt), for example about 15%:85% (wt/wt), about 30%:70% (wt/wt) or about 40%:60% (wt/wt). Each possibility represents a separate embodiment of the present invention. Preferably, the first component comprises 50% or less of the pregabalin active ingredient, for example 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the total pregabalin dose. Preferably, the second component comprises 50% or more of the pregabalin active ingredient, for example 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the total pregabalin dose. Any combination of such proportion is encompassed by the scope of the present invention. Each possibility represents a separate embodiment of the present invention. In some embodiments, the compositions comprise from about 200 to about 550 mg pregabalin in the first component, and from about 50 to about 250 mg pregabalin in the second component. In other embodiments, the compositions comprise from about 200 to about 400 mg pregabalin in the first component, and from about 50 to about 150 mg pregabalin in the second component. In other embodiments, the compositions comprise from about 250 mg pregabalin in the first component, and about 100 mg pregabalin in the second component. Each possibility represents a separate embodiment of the present invention.
- The pharmaceutical compositions of the present invention are useful in treating a condition or disorder which is responsive to pregabalin treatment. Thus, in additional embodiments, the present invention relates to a method of treating a condition or disorder which is responsive to pregabalin treatment, by administering the extended-release formulations of the present invention. In other embodiments, the present invention relates to the use of the extended-release formulations of the invention for treating a condition or disorder which is responsive to pregabalin treatment. Within the scope of the present invention is the use of a pharmaceutical condition of disorder which is responsive to pregabalin treatment.
- In some embodiments, the condition or disorder is selected from epilepsy, pain, diabetic peripheral neuropathy, postherpetic neuralgia, physiological condition associated with psychomotor stimulants, inflammation, gastrointestinal damage, alcoholism, insomnia, fibromyalgia, anxiety, depression, mania and bipolar disorder, and any combinations thereof. Each possibility represents a separate embodiment of the invention.
- The present invention is also directed to a composition comprising pregabalin or other active ingredient used for the treatment of a neurological disorder or injury selected from the group consisting of epilepsy, in the treatment of seizures secondary to stroke, head/brain trauma or peri- or post-operative neurosurgery, multiple sclerosis, or involuntary action tremors. The present invention is also directed to a composition comprising pregabalin or other active ingredient used for the treatment of chronic pain associated with neuropathic, muscular and skeletal pain, tardive dyskinesia or migraines, reflex sympathetic dystrophy syndrome (RSD) [also known as complex regional pain syndrome (CRPS)] and fibromyalgia or muscle disorders. The present invention is also directed to a composition comprising psychiatric disorders such as, but not limited, to bipolar disease, panic, anxiety, depression, alcoholism and manic behavior. The formulations or compositions may also be used to treat the conditions described in U.S. Pat. No. 6,310,098 (which is incorporated herein by reference) and in particular hormonal variation in menopausal other related syndromes of hot flashes, fever, nausea and emesis. The present invention is also directed to treatment of symptoms of post menopausal woman selected from the group consisting of urge incontinence, vaginal dryness, and dry eye syndrome.
- The term “therapeutically effective amount” or “an effective amount” as used herein refers to a quantity of a compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered. The effective amount, according to the principles of the present invention can be determined by any one of ordinary skill in the art and can be tested on various models both in vitro and in vivo.
- The term “treating” as used herein refers to stopping or slowing down the progression of the particular disease or disorder being treated. The term “treating” further includes the reduction in the occurrence of various symptoms associated with the disease or disorder being treated.
- As used herein, the term “administering” refers to bringing a subject in contact with the compositions of the present invention. In one embodiment, the present invention encompasses administering the compositions of the present invention to a human subject.
- The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.
-
-
TABLE 1 composition 1 Component Weight Function First Layer (Fast ER): Pregabalin 250 mg API HPMC K4M 50 mg Release Controlling Polymer Hydroxypropylcellulose 50 mg Binder and Release (Klucel LF) Controlling Polymer Silicon Dioxide (Syloid 244) 1 mg Glidant Mg Stearate 0.5 mg Lubricant Second Layer (Slow ER) Pregabalin 100 mg API HPMC K100M 50 mg Release Controlling Polymer Ethyl cellulose (Ethocel) 50 mg Release Controlling Polymer Silicon Dioxide (Syloid 244) 1 mg Glidant Mg Stearate 0.5 mg Lubricant - The First (Fast ER) Layer is prepared by mixing Pregabalin, KLUCEL and HPMC, adding 100 ml water, then high shear granulation for 1 minute, drying in fluid bed and milling in a 0.8 mm screen.
- The Second (Slow ER) layer is prepared by mixing pregabalin, HPMC and Ethyl cellulose. 50 ml ethanol are added, followed by high shear granulation for 1 minute, drying in a fluid bed and milling in a 0.8 mm screen.
- The two layers are compressed together in Picolla rotary tableting machine to provide the desired double layer tablets.
-
-
TABLE 2 composition 2 Component Weight Function First Layer (Fast ER): Pregabalin 250 mg API HPMC K4M 50 mg Release Controlling Polymer Hydroxypropylcellulose 50 mg Binder and Release (Klucel LF) Controlling Polymer Silicon Dioxide (Syloid 244) 1 mg Glidant Mg Stearate 0.5 mg Lubricant Second Layer (Slow ER) Pregabalin 100 mg API HPMC K100M 50 mg Release Controlling Polymer Ethyl cellulose (Ethocel) 50 mg Release Controlling Polymer Silicon Dioxide (Syloid 244) 1 mg Glidant Mg Stearate 0.5 mg Lubricant - The First (Fast ER) Layer is based on a matrix similar to the one used for the double layer tablets, but after screening the 250 mg pregabalin mixed with 50 mg HPMC K4M, 50 mg Klucel LF, 1 mg Syloid 244 and 0.5 mg Mg Stearate is compressed into several minitabs with a diameter of 2 mm which release the pregabalin in a pH independent manner for 6 hrs.
- The second type of minitabs, the Slow Layer is composed of 100 mg pregabalin mixed with 50 mg HPMC K100M, 50
mg Ethocel 20 cp, 1 mg Syloid 244 and 0.5 mg Mg Stearate compressed into several minitabs with diameter of 2 mm which release the pregabalin in a pH independent manner for 24 hrs. - 500 gr Pregabalin are mixed with 15 gr PVP K30. The mixture is solubilized in 2 liter ethanol/water, 50%:50% mixture.
- The pregabalin mixture is sprayed over 45/50 mesh sugar spheres fluidized in a fluid bed equipped with a Wurster column.
- HPMC 5 cp is sprayed over the pregabalin layer, providing 2% w/w isolating layer.
- The HPMC coated beads are separated into two sub groups:
- 1. Fast ER Beads: a mixture of
ethyl cellulose 20 cp mixed with 10% w/w Dibutylsebacate and 2% Klucel LF as plastisizers is coated to a level of 10% w/w total coating of the polymer layer, based on the total bead weight. - 2. Slow ER Beads: a mixture of
ethyl cellulose 20 cp mixed with 10% w/w Dibutylsebacate and 2% Klucel LF as plastisizers is coated to a level of 25% w/w total coating of the polymer layer, based on the total bead weight. - The two bead groups are mixed at a ratio of 75% Fast beads with 25% Slow beads in doses ranging from 100 mg to 500 mg total.
- 500 gr Pregabalin are mixed with 500 gr Avicel 101(microcrystalinecellulose) and 20
gr HPMC 50 cp. The mixture is wetted with 0.8 liter water. - HPMC 5 cp is sprayed over the pregabalin mixture, providing a 2% w/w isolating layer.
- The pregabalin mixture is then passed through an extruder with 1 mm screen, followed by spheronization and drying in a fluid bed equipped with Wurster column.
- The dry pregabalin beads are separated into two sub populations:
- 1. Fast ER Beads: a mixture of
ethyl cellulose 20 cp mixed with 10% w/w Dibutylsebacate and 2% Klucel LF as plastisizers is coated over the beads to a level of 10% w/w total coating of the polymer layer, based on the total bead weight. - 2. Slow ER Beads: a mixture of ethyl cellulose 220 cp mixed with 10% w/w Dibutylsebacate and 2% Klucel LF as plastisizers is coated over the beads to a level of 25% w/w total coating of the polymer layer, based on the total bead weight.
- The two beads groups are mixed in a ratio of 85% Fast beads with 15% Slow beads in doses ranging from 50 mg to 600 mg total.
-
-
TABLE 3 Fast ER minitab formulation Component Weight Function PART 1 Pregabalin 301.3 mg API Ethyl cellulose (Ethocel) 140.0 mg Release Controlling Polymer Water as needed PART 2 Glyceryl Behenate 60.0 mg Lubricant/matrix former Silicon Dioxide (Syloid 244) 0.98 mg Glidant PART III Mg Stearate 5.00 mg Lubricant -
TABLE 4 Slow XR minitab formulation Component Weight Function PART 1 Pregabalin 301.3 mg API Ethyl cellulose (Ethocel) 140.0 mg Release Controlling Polymer Water as needed PART 2 Glyceryl Behenate 60.0 mg Lubricant/matrix former Silicon Dioxide (Syloid 244) 0.98 mg Glidant PART III Mg Stearate 5.00 mg Lubricant PART IV Surelease (ethyl cellulose 13.0 mg Release Controlling dispersion) Polymer Polyvinyl alcohol 1.3 mg Subcoat -
-
TABLE 5 Fast ER minitab formulation Component Weight Function Part I Pregabalin 300 mg API Ethyl cellulose (Ethocel) 140 mg Release controlling polymer Water as needed Part II Glyceryl Behenate 60 mg Lubricant/matrix former Part III Mg stearate 5 mg Lubricant -
TABLE 6 Slow XR minitab formulation Component Weight Function Part I Pregabalin 300 mg API Ethyl cellulose (Ethocel) 140 mg Release controlling polymer Water as needed Part II Glyceryl Behenate 60 mg Lubricant/matrix former Part III Mg stearate 5 mg Lubricant Part IV Surelease (ethyl cellulose 13 mg Release controlling dispersion) polymer - Pregabalin mini-tablets were prepared according to the following process: Pregabalin and ethocel were mixed in a Diosna mixture, adding water as needed. The wet granulation mixture was placed in a Fluid Bed Dryer and dried at −50° C. The dried mixture was screened through a 0.710 mm screen. Glyceryl Behenate and Magnesium Stearate were added to the mixture sequentially followed by mixing in a V-blender. The obtained power mixtures were compressed at a compressing pressure of about 4.5 tons to prepare uncoated mini-tablets (the Fast ER minitabs) with a diameter of 3 mm.
- A portion of the uncoated tablets were coated with a solution of Surelease 19040 (10.0 g): water (6.97 g), resulting in pregabalin Slow ER minitabs.
- The weight of minitabs for each ratio were weighed and filled inside gelatin capsules (size 00). The ratio between the “fast” ER and the “slow” ER minitabs can be adjusted to the required human PK profile. The proportions in each dose between the Fast ER minitabs and the Slow ER minitabs is between about 50%:50% (wt/wt) to about 10%:90% (wt/wt), more preferably 40%:60% to 30%:70%.
-
-
TABLE 7 Fast ER minitab formulation Component Weight Function PART 1 Pregabalin 300 mg API Hypromellose (Methocel ™E50) 120 Release Controlling Polymer Hypromellose (Methocel ™E4M) 16 Release Controlling Polymer Hypromellose (Methocel ™K15M) 56 Release Controlling Polymer Hydroxypropylcellulose (Klucel 2 Release Controlling Polymer LF) Water as needed PART II Mg Stearate 2.5 Lubricant -
TABLE 8 Slow ER minitab formulation Component Weight Function PART 1 Pregabalin 300 mg API Hypromellose (Methocel ™E50) 120 Release Controlling Polymer Hypromellose (Methocel ™E4M) 16 Release Controlling Polymer Hypromellose (Methocel ™K15M) 56 Release Controlling Polymer Hydroxypropylcellulose (Klucel LF) 2 Release Controlling Polymer Water as needed PART II Mg Stearate 2.5 Lubricant PART III Surelease E-7-19040 9.9 Release Controlling Polymer - Pregabalin, Hypromellose (Methocel™E50), Hypromellose (Methocel™E4M), Hypromellose (Methocel™K15M), Hydroxypropylcellulose (Klucel LF) were mixed in a Diosna Mixer, adding water as needed. The wet granulation mixture was placed in a Fluid Bed Dryer and dried at −50° C. The dried mixture was screened through a 0.710 mm screen. Magnesium Stearate was added to the mixture sequentially followed by mixing in a V-blender. The tableting, coating and filling in gelatin capsules was carried out as described in Example 6.
- The objective of the study was to compare the in vivo and in vitro release profiles of pregabalin extended release (ER) capsules according to the present invention, and a pregabalin immediate release (IR) formulation. The formulations are described in Table 9.
-
TABLE 9 Pregabalin ER and IR formulations Name Strength Pregabalin ER 300 mg/capsule (Example 6) (fast ER:slow ER = 40:60) Pregabalin IR 75 mg/capsule (Lyrica ®) - For in vivo release determination, a single oral administration of 300 mg extended release capsules or immediate release capsules was given to dogs, and blood was collected from forelimb vein at 0, 10 min, 30 min, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 6 h, 7 h, 9 h, 12 h, 15 h, 18 h, 24 h, 30 h, and 48 h/72 h. The concentration of Pregabalin in the blood was determined by HPLC-MS.
- In vitro dissolution was determined by HPLC, using phosphate buffer pH 6.8 and acetonitrile as the mobile phase according to the following parameters:
- Sampling Time: 1; 6; 9; 16; and 24 h
- Sampling volume: 5 mL
-
-
Column Equisil BDS-C8, 5 μm, 150 mm × 4.6 mm ID Flow 1.0 mL/min Wavelength 200 nm Injection volume 20 μL Runtime 7 minutes Oven Temperature 30° C. -
FIG. 1 depicts the plasma concentration vs. time profile of a pregabalin extended release (ER) formulation (∘) according to the present invention and pregabalin immediate release (IR) (▪) formulation. - For Pregabalin ER, the Tmax was 7.83 h, MRT(0-t) was 17.07 h, Cmax was 17940.148 ug/L, and the plasma concentration was above 10000 ug/L within 18 h.
- For Pregabalin IR, the Tmax was 2.67 h, MRT(0-t) was 12.32 h, and Cmax was 35789.67 ug/L.
-
FIG. 2 depicts the in vitro (♦) and in vivo (▴) release profile of a pregabalin extended release (ER) formulation according to the present invention. - The release rate of extended release capsules according to the invention in dogs was relatively stable, and the mean retention time was longer, both of which showed good extended release effect. Compared to the common capsules (Lyrica® immediate release formulation), the extended release capsules of the present invention showed a lower Cmax, a longer Tmax, a much more stable release rate, and a much longer MRT, all of which indicated its significant extended release properties. The release rates of pregabalin in vivo and in vitro showed a certain degree of similarity, indicating good in vivo-in-vitro correlation.
- While certain embodiments of the invention have been illustrated and described, it will be clear that the invention is not limited to the embodiments described herein. Numerous modifications, changes, variations, substitutions and equivalents will be apparent to those skilled in the art without departing from the spirit and scope of the present invention as described by the claims, which follow.
Claims (19)
1. An oral, extended-release (ER) pharmaceutical composition comprising as an active ingredient pregabalin or a salt thereof and a pharmaceutically acceptable carrier or excipient, wherein the composition comprises two components each containing pregabalin or a salt thereof comprising a first component that provides pH independent controlled release of the pregabalin active ingredient contained therein over a time period of about 4 to about 6 hours, and a second component that provides pH independent controlled release of the pregabalin active ingredient contained therein over a time period of about 24 hours.
2. The composition of claim 1 , wherein the ratio of the first component to the second component is from about 50%:50% (wt/wt) to about 10%:90% (wt/wt).
3. The composition of claim 2 , wherein the ratio of the first component to the second component is about 30%:70% (wt/wt) or about 40%:60% (wt/wt).
4. The composition of claim 1 , wherein the ratio of the first component to the second component is from about 50%:50% (wt/wt) to about 90%:10% (wt/wt).
5. The composition of claim 4 , wherein the ratio of the first component to the second component is from about 30%:70% (wt/wt) or about 40%:60% (wt/wt).
6. The composition of claim 1 , wherein the composition is adapted for once-daily administration.
7. The composition of claim 1 , wherein the first component and the second component each independently comprises at least one pharmaceutically acceptable excipient selected from the group consisting of a pH-independent release controlling polymer, a binder, a glidant, a plasticizer, a matrix former, a disintegrant, a lubricant, and any combination thereof.
8. The composition of claim 7 , wherein the first component and the second component each comprises at least one pH-independent release controlling polymer selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), polyvinylpyrrolidone (PVP), ethyl cellulose (EC), cellulose acetate, acrylic polymers, and combinations thereof.
9. The composition of claim 7 , wherein the pH-independent release controlling polymer is selected from the group consisting of hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose (EC), and any combination thereof.
10. The composition of claim 7 , wherein the binder is selected from the group consisting of hydroxypropyl cellulose (HPC) and polyvinylpyrrolidone (PVP).
11. The composition of claim 7 , wherein the lubricant is selected from the group consisting of magnesium stearate, glyceryl behenate and sodium stearyl fumarate.
12. The composition of claim 7 wherein the glidant is silicon dioxide.
13. The composition of claim 1 , wherein the first component and the second component each comprise pregabalin, ethyl cellulose, glyceryl behenate and magnesium stearate.
14. The composition of claim 13 , wherein the first component is uncoated and wherein the second component further comprises a coating comprising ethyl cellulose.
15. The composition of claim 1 , wherein the first component and the second component are each in the form of ER beads or mini-tablets comprising pregabalin, a first pH-independent release controlling polymer, at least one lubricant and/or matrix former, and a coating comprising a second pH-independent release controlling polymer which may be the same or different from the first pH-independent release controlling polymer, wherein the same coating in different amounts, is used for the first and second components.
16. The composition of claim 1 , wherein pregabalin in each component is released in a controlled release order selected from the group consisting of zero, first, second and third release order, and any pseudo orders thereof.
17. The composition of claim 1 , wherein pregabalin is released from the pharmaceutical composition to provide a lower Cmax, a smaller index of fluctuation, and/or a reduced side effects profile as compared to a similar dose of an immediate release formulation of pregabalin.
18. A method of treating a condition or disorder which is responsive to pregabalin treatment, comprising the step of administering to a subject in need thereof an effective amount of the oral, extended-release (ER) pharmaceutical composition of claim 1 .
19. The method of claim 18 , wherein the condition or disorder selected from the group consisting of epilepsy, pain, diabetic peripheral neuropathy, postherpetic neuralgia, physiological condition associated with psychomotor stimulants, inflammation, gastrointestinal damage, alcoholism, insomnia, fibromyalgia, anxiety, depression, mania and bipolar disorder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/313,274 US20210260006A1 (en) | 2016-07-17 | 2021-05-06 | Extended release dosage forms of pregabalin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662363267P | 2016-07-17 | 2016-07-17 | |
PCT/IL2017/050802 WO2018015946A1 (en) | 2016-07-17 | 2017-07-16 | Extended release dosage forms of pregabalin |
US201916318308A | 2019-01-16 | 2019-01-16 | |
US17/313,274 US20210260006A1 (en) | 2016-07-17 | 2021-05-06 | Extended release dosage forms of pregabalin |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2017/050802 Continuation WO2018015946A1 (en) | 2016-07-17 | 2017-07-16 | Extended release dosage forms of pregabalin |
US16/318,308 Continuation US11026908B2 (en) | 2016-07-17 | 2017-07-16 | Extended release dosage forms of pregabalin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210260006A1 true US20210260006A1 (en) | 2021-08-26 |
Family
ID=60992289
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/318,308 Active US11026908B2 (en) | 2016-07-17 | 2017-07-16 | Extended release dosage forms of pregabalin |
US17/313,274 Pending US20210260006A1 (en) | 2016-07-17 | 2021-05-06 | Extended release dosage forms of pregabalin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/318,308 Active US11026908B2 (en) | 2016-07-17 | 2017-07-16 | Extended release dosage forms of pregabalin |
Country Status (8)
Country | Link |
---|---|
US (2) | US11026908B2 (en) |
EP (1) | EP3484456A4 (en) |
CN (1) | CN109475510B (en) |
AU (1) | AU2017300185B2 (en) |
BR (1) | BR112019000636A2 (en) |
CA (1) | CA3030105A1 (en) |
IL (1) | IL263941B (en) |
WO (1) | WO2018015946A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017300185B2 (en) * | 2016-07-17 | 2023-02-02 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
KR102631399B1 (en) * | 2018-03-30 | 2024-02-01 | 씨지인바이츠 주식회사 | Pharmaceutical composition comprising polmacoxib and pregabalin for treatment of pain |
US11938222B2 (en) * | 2018-06-13 | 2024-03-26 | Beijing Tide Pharmaceutical Co., Ltd. | Pregabalin sustained release composition and method for preparing the same |
CA3105212A1 (en) * | 2018-06-28 | 2020-01-02 | Mylan Inc. | Pregabalin extended-release formulations |
WO2021181262A1 (en) * | 2020-03-09 | 2021-09-16 | Almendro Properties And Trading Llp | Controlled release formulations comprising drotaverine or salt thereof |
KR20230117591A (en) | 2020-12-04 | 2023-08-08 | 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. | Stable coated, solid pharmaceutical composition containing an opioid analgesic and an anticonvulsant for pain relief |
WO2022256545A1 (en) * | 2021-06-04 | 2022-12-08 | Nevakar Injectables Inc. | Injectable pregabalin formulations |
CN114983951B (en) * | 2021-12-24 | 2023-11-07 | 微研优仿医药科技(江苏)有限公司 | Gastric floating tablet composition and preparation method thereof |
CN116850153B (en) * | 2023-06-12 | 2024-02-06 | 则正(上海)生物科技有限公司 | Pregabalin pharmaceutical composition and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898736A (en) * | 1988-03-09 | 1990-02-06 | Merck & Co., Inc. | Method for tablet preparation |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US20140161880A1 (en) * | 2011-07-26 | 2014-06-12 | Yuhan Corporation | Sustained release tablet comprising pregabalin through two-phase release-controlling system |
US11026908B2 (en) * | 2016-07-17 | 2021-06-08 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60034344T2 (en) | 1999-07-22 | 2008-01-10 | University Of Rochester | METHOD FOR TREATING THE SYMPTOMS OF HORMONAL CHANGES, INCLUDING HEAD FORESTS |
ES2240313T3 (en) | 2000-12-07 | 2005-10-16 | Warner-Lambert Company Llc | PROCEDURE AND SYSTEM FOR THE UNIFORM RELEASE OF A PHARMACO. |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20060094782A9 (en) | 2003-10-31 | 2006-05-04 | Wong Patrick S | Compositions and dosage forms for enhanced absorption |
US20060159233A1 (en) * | 2005-01-19 | 2006-07-20 | Cotton John M | Re-arrangeable analog electrical cross connect |
CN101137352A (en) * | 2005-01-21 | 2008-03-05 | 诺瓦制药公司 | Pharmaceutical formulations and methods of use |
NL2000281C2 (en) * | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical compositions containing pregabalin. |
CN1857244A (en) | 2006-03-06 | 2006-11-08 | 重庆医药工业研究院有限责任公司 | Slow released pregabalin medicine composition |
US8454993B2 (en) * | 2007-11-23 | 2013-06-04 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
US20100159001A1 (en) | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
KR101573889B1 (en) | 2009-10-09 | 2015-12-04 | 영진약품공업주식회사 | Immediate-release and sustained-release pharmaceutical composition |
KR101317592B1 (en) | 2009-10-28 | 2013-10-15 | 씨제이제일제당 (주) | Gastric-retentive sustained release fomulation containing pregabalin and pva-peg graft copolymer |
KR101648490B1 (en) | 2009-11-02 | 2016-08-17 | 한미사이언스 주식회사 | Sustained release oral preparation using gastric retentive drug delivery system |
EP2615913A4 (en) * | 2010-09-17 | 2014-03-19 | Panacea Biotec Ltd | Sustained release pharmaceutical compositions comprising pregabalin |
MA44212A (en) * | 2015-05-26 | 2018-12-26 | Isa Odidi | Sustained-release pregabalin |
-
2017
- 2017-07-16 AU AU2017300185A patent/AU2017300185B2/en active Active
- 2017-07-16 EP EP17830599.1A patent/EP3484456A4/en active Pending
- 2017-07-16 WO PCT/IL2017/050802 patent/WO2018015946A1/en unknown
- 2017-07-16 CA CA3030105A patent/CA3030105A1/en active Pending
- 2017-07-16 US US16/318,308 patent/US11026908B2/en active Active
- 2017-07-16 BR BR112019000636-2A patent/BR112019000636A2/en active Search and Examination
- 2017-07-16 CN CN201780044181.XA patent/CN109475510B/en active Active
-
2018
- 2018-12-24 IL IL263941A patent/IL263941B/en unknown
-
2021
- 2021-05-06 US US17/313,274 patent/US20210260006A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898736A (en) * | 1988-03-09 | 1990-02-06 | Merck & Co., Inc. | Method for tablet preparation |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US20140161880A1 (en) * | 2011-07-26 | 2014-06-12 | Yuhan Corporation | Sustained release tablet comprising pregabalin through two-phase release-controlling system |
US11026908B2 (en) * | 2016-07-17 | 2021-06-08 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
Non-Patent Citations (2)
Title |
---|
"Immediate Release vs. Extended Release Medications" Revive Pain Management. Nov. 17, 2022, accessed online at <https://www.revivepain.com/blog/859803-immediate-release-vs-extended-release-medications>. (Year: 2022) * |
K.P. Sampath Kumar et al. "Sustained Release Drug Delivery System Potential", Pharma Innovation 2012;1(2):48-60. (Year: 2012) * |
Also Published As
Publication number | Publication date |
---|---|
WO2018015946A1 (en) | 2018-01-25 |
CN109475510A (en) | 2019-03-15 |
CN109475510B (en) | 2023-03-10 |
AU2017300185A1 (en) | 2019-01-24 |
US20190298675A1 (en) | 2019-10-03 |
BR112019000636A2 (en) | 2019-04-30 |
US11026908B2 (en) | 2021-06-08 |
CA3030105A1 (en) | 2018-01-25 |
EP3484456A1 (en) | 2019-05-22 |
IL263941A (en) | 2019-02-28 |
IL263941B (en) | 2022-01-01 |
AU2017300185B2 (en) | 2023-02-02 |
EP3484456A4 (en) | 2020-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210260006A1 (en) | Extended release dosage forms of pregabalin | |
KR100475759B1 (en) | Sustained release ranolazine formulations | |
AU2013344281B2 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
CN109310642B (en) | Oral medicine composition of mesalazine | |
US20100112053A1 (en) | Gastric retention-type sustained-release levodopa preparation | |
CA2739751C (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
US10561602B2 (en) | Controlled extended release pregabalin | |
US20100247645A1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
US20140050784A1 (en) | Pharmaceutical compositions of memantine | |
US20200101053A1 (en) | Method of treating heart failure with preserved ejection fraction by administering milrinone | |
JP2012516299A (en) | Organic galenic formulation | |
US20070160667A1 (en) | Controlled release formulation of divalproex sodium | |
US20130251793A1 (en) | Pharmaceutical composition comprising phentermine and topiramate | |
EP1815850B1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
EP3796908B1 (en) | Controlled release propiverine formulations | |
CN107616969B (en) | Rapidly disintegrating pharmaceutical composition of Perampanel tablets | |
US20200338025A1 (en) | Extended release midodrine hydrochloride compositions and methods of use | |
WO2024081554A2 (en) | Modified release tolcapone formulations | |
MANUBHAI | DEVELOPMENT AND EVALUATION OF ORAL EXTENDED RELEASE FORMULATION OF ANTI HYPERTENSIVE DRUG | |
WO2015063670A1 (en) | Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |